Pembrolizumab plus olaparib for stage 4 pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a DNA-repair drug) can work better for people with metastatic (stage 4) pancreatic cancer. It targets tumors with certain lab marker results and aims to improve control of cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent forms
- Have pancreatic cancer confirmed under a microscope (biopsy or body-fluid test)
- Have stage 4 metastatic pancreatic ductal adenocarcinoma with at least one measurable spot on scans
- Your tumor test must show one of these: low “TMB” threshold (TMB >4 mutations per megabase), or a mismatch-repair change (dMMR), or MSI-H (an instability marker)
- Have had 0 to 1 prior chemotherapy treatment for unresectable (stage 3 or 4) pancreatic cancer
- Be able to do treatment safely: good blood counts, liver and kidney test results, and be active enough (ECOG 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a new drug called olaptesed combined with immunotherapy (pembrolizumab) and either one of two standard chemotherapy regimens for people with advanced pancreatic cancer that has stopped responding to first-line treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.